These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 9133508)

  • 1. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Gottdiener JS; Reda DJ; Massie BM; Materson BJ; Williams DW; Anderson RJ
    Circulation; 1997 Apr; 95(8):2007-14. PubMed ID: 9133508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents.
    Gottdiener JS; Reda DJ; Williams DW; Materson BJ; Cushman W; Anderson RJ
    Circulation; 1998 Jul; 98(2):140-8. PubMed ID: 9679720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial.
    Cushman WC; Materson BJ; Williams DW; Reda DJ
    Hypertension; 2001 Oct; 38(4):953-7. PubMed ID: 11641316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Materson BJ; Reda DJ; Cushman WC; Massie BM; Freis ED; Kochar MS; Hamburger RJ; Fye C; Lakshman R; Gottdiener J
    N Engl J Med; 1993 Apr; 328(13):914-21. PubMed ID: 8446138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group.
    Papademetriou V; Gottdiener JS; Narayan P; Cushman WG; Zachariah PK; Gottdiener PS; Chase GA
    J Am Coll Cardiol; 1997 Dec; 30(7):1802-8. PubMed ID: 9385910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Lakshman MR; Reda DJ; Materson BJ; Cushman WC; Freis ED
    Arch Intern Med; 1999 Mar; 159(6):551-8. PubMed ID: 10090111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Preston RA; Materson BJ; Reda DJ; Williams DW; Hamburger RJ; Cushman WC; Anderson RJ
    JAMA; 1998 Oct; 280(13):1168-72. PubMed ID: 9777817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of detectable regression of human hypertensive left ventricular hypertrophy following drug treatment for 1 year.
    Laufer E; Reid C; Qi XL; Jennings GL
    Clin Exp Pharmacol Physiol; 1998; 25(3-4):208-15. PubMed ID: 9590570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
    Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
    Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
    JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Materson BJ; Reda DJ; Preston RA; Cushman WC; Massie BM; Freis ED; Kochar MS; Hamburger RJ; Fye C; Lakshman R
    Arch Intern Med; 1995 Sep; 155(16):1757-62. PubMed ID: 7654109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters. The HANE Trial Research Group.
    Kribben A; Anlauf M; Distler A; Gärtner H; Holzgreve H; Michaelis J; Röcker L; Schäfers R; Philipp U; Wellek S; Philipp T
    Kidney Int Suppl; 1997 Oct; 61():S74-6. PubMed ID: 9328972
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
    Kraiczi H; Hedner J; Peker Y; Grote L
    Am J Respir Crit Care Med; 2000 May; 161(5):1423-8. PubMed ID: 10806134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group.
    Os I; Hotnes T; Dollerup J; Mogensen CE
    Am J Hypertens; 1997 Aug; 10(8):899-904. PubMed ID: 9270085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing.
    Pelttari LH; Hietanen EK; Salo TT; Kataja MJ; Kantola IM
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):272-9. PubMed ID: 9544866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients.
    Agabiti-Rosei E; Zulli R; Muiesan ML; Salvetti M; Rizzoni D; Corbellini C; Monteduro C
    Blood Press; 1998 May; 7(3):160-9. PubMed ID: 9758086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.